Evotec Opens Integrated Biologics Manufacturing Facility

Published on: 

The Just - Evotec Biologics facility in Redmond, Wash., uses the company’s J.POD technology.

Evotec SE announced the opening of its J.POD 1 late-stage clinical and commercial biologics biomanufacturing facility, in Redmond, Wash., part of Just - Evotec Biologics' J.DESIGN platform, which integrates data analytics and machine learning for the discovery, development, and manufacturing of biologic drugs.

The current good manufacturing practice (cGMP) facility, which totals 130,000 sq.ft. and uses J.POD technology, features a manufacturing ballroom and autonomous cleanrooms to run small, intensified product processes with fed-batch or continuous processing up to 1000 L scale and deliver clinical- or commercial-grade drug substance in batchs of a few kilograms to metric tons, the company reported in an Aug. 11, 2021 press statement.

The site also has dedicated quality control and process development laboratories, a warehouse, and office and meeting space for approximately 200 employees at full capacity.

The facility was constructed in 19 months, a construction schedule that is faster relative to traditional biologics manufacturing, the company reports, reducing costs and promoting sustainability. The facility is designed to use less water, electricity, and chemicals compared with conventional facilities.


"Evotec's mission is all about access to innovative, highly effective medicines.” said Evotec CEO Wener Lanthaler in a company press release. “With this uniquely flexible manufacturing facility, Evotec now has the capabilities in house to not only discover and develop innovative biologics therapies, but also deliver them to the patients who urgently need them.”

Source: Evotech